February 9, 2018 / 8:48 AM / 16 days ago

BRIEF-‍Janssen Submits Marketing Authorisation Application To EMA For Apalutamide

Feb 9 (Reuters) -

* ‍JANSSEN SUBMITS MARKETING AUTHORISATION APPLICATION FOR APALUTAMIDE TO TREAT PATIENTS WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER​

* ‍JANSSEN PHARMACEUTICAL - SUBMITTED MARKETING AUTHORISATION APPLICATION TO EUROPEAN MEDICINES AGENCY (EMA) FOR APALUTAMIDE​ Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below